SCYNEXIS, Inc. (SCYX) |
|
1.87 0.065 (3.6%)
|
03-24 16:00 |
|
Open: |
1.75 |
Pre. Close: |
1.805 |
|
High:
|
1.9587 |
Low:
|
1.75 |
|
Volume:
|
679,043 |
Market Cap:
|
61(M) |
|
|
|
Technical analysis |
as of: 2023-03-24 4:29:40 PM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 2.66 One year: 3.11 |
| Support: |
Support1: 1.58 Support2: 1.14 |
| Resistance: |
Resistance1: 2.27 Resistance2: 2.66 |
| Pivot: |
1.5  |
| Moving Average: |
MA(5): 1.67 MA(20): 1.53
MA(100): 1.79  MA(250): 2.18 |
| MACD: |
MACD(12,26): 0 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 65.6 %D(3): 55.7 |
| RSI: |
RSI(14): 61.1 |
| 52-week: |
High: 4.03 Low: 1.14 |
| Average Vol(K): |
3-Month: 406 (K) 10-Days: 1,936 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ SCYX ] has closed below upper band by 15.1%. Bollinger Bands are 68.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.96 - 1.97 |
1.97 - 1.98 |
|
Low:
|
1.73 - 1.74 |
1.74 - 1.75 |
|
Close:
|
1.85 - 1.87 |
1.87 - 1.88 |
|
Company Description |
|
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey. |
Headline News |
Fri, 24 Mar 2023
SCYNEXIS Inc : A loss of 44 cents per share anticipated ... - Kalkine Media
Wed, 22 Mar 2023
Candida Auris Warning Drives 98% Gain in Anti-Fungus Scynexis ... - Bloomberg
Wed, 22 Mar 2023
Why Edible Garden Shares Are Trading Lower By Over 26%? Here ... - Investing.com UK
Wed, 22 Mar 2023
Healthcare Stocks Moving Up and Down Wednesday: SCYX, ETNB, INM, ATHX, MHUA, NCNA, MRKR, PXMD - InvestorsObserver
Wed, 22 Mar 2023
SCYNEXIS, Inc. (NASDAQ:SCYX) insiders are still down US$113k after purchasing last year, recent gain helped regain some losses - Yahoo Eurosport UK
Wed, 22 Mar 2023
SCYNEXIS Inc (SCYX) Up 7.05% in Premarket Trading - InvestorsObserver
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Drug Manufacturers—Specialty & Generic |
| Shares Out. |
0 (M) |
| Shares Float |
33 (M) |
|
% Held by Insiders
|
2.872e+007 (%) |
|
% Held by Institutions
|
1.9 (%) |
|
Shares Short
|
956 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-8.488e+007 |
|
EPS Est Next Qtl
|
-0.37 |
|
EPS Est This Year
|
-1.12 |
|
EPS Est Next Year
|
-1.37 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-2 |
|
Return on Assets (ttm)
|
55 |
|
Return on Equity (ttm)
|
-48.2 |
|
Qtrly Rev. Growth
|
4.16e+006 |
|
Gross Profit (p.s.)
|
100.84 |
|
Sales Per Share
|
-141.59 |
|
EBITDA (p.s.)
|
6.425e+006 |
|
Qtrly Earnings Growth
|
-5.2 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-83 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.02 |
|
Price to Cash Flow
|
3.22 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
879240 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2020-07-16 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
